Propensity Matched Outcomes of Minimally Invasive Mitral Surgery: Does a Heart-Team Approach Eliminate Female Gender as an Independent Risk Factor?

female gender an independent risk factor heart team minimally invasive mitral surgery

Journal

Journal of personalized medicine
ISSN: 2075-4426
Titre abrégé: J Pers Med
Pays: Switzerland
ID NLM: 101602269

Informations de publication

Date de publication:
03 Jun 2023
Historique:
received: 29 03 2023
revised: 31 05 2023
accepted: 01 06 2023
medline: 28 6 2023
pubmed: 28 6 2023
entrez: 28 6 2023
Statut: epublish

Résumé

There is increasing evidence that female gender is an independent risk factor for cardiac surgery. Minimally invasive mitral surgery (MIV) has proven to have excellent long-term results, but little is known about gender-dependent outcomes. The aim of our study was to analyze our heart team's decision-based MIV-specialized cohort. In-hospital and follow-up data were retrospectively collected. The cohort was divided into gender groups and propensity-matched groups. Between 22 July 2013 and 31 December 2022, 302 consecutive patients underwent MIV. Before matching, the total cohort showed that women were older, had a higher EuroSCORE II, were more symptomatic, and had more complex valve pathology and tricuspid regurgitation resulting in more valve replacements and tricuspid repairs. Intensive and hospital stays were longer. In-hospital deaths (n = 3, all women) were comparable, with more atrial fibrillation in women. The median follow-up time was 3.44 (0.008-8.9) years. The ejection fraction, NYHA, and recurrent regurgitation were low and comparable and atrial fibrillation more frequent in women. The calculated 5-year survival and freedom from re-intervention were comparable ( Despite women being older and sicker, with more complex valve pathology and subsequent replacement, early and mid-term mortality and the need for reoperation were low and comparable before and after propensity matching, which might be the result of the MIV setting combined with our patient-tailored decision-making. We believe that a multidisciplinary heart team approach is crucial to optimize patient outcomes in MIV, and it might also reduce the widely reported increased surgical risk in female patients. Further studies are needed to prove our findings.

Sections du résumé

BACKGROUND BACKGROUND
There is increasing evidence that female gender is an independent risk factor for cardiac surgery. Minimally invasive mitral surgery (MIV) has proven to have excellent long-term results, but little is known about gender-dependent outcomes. The aim of our study was to analyze our heart team's decision-based MIV-specialized cohort.
METHODS METHODS
In-hospital and follow-up data were retrospectively collected. The cohort was divided into gender groups and propensity-matched groups.
RESULTS RESULTS
Between 22 July 2013 and 31 December 2022, 302 consecutive patients underwent MIV. Before matching, the total cohort showed that women were older, had a higher EuroSCORE II, were more symptomatic, and had more complex valve pathology and tricuspid regurgitation resulting in more valve replacements and tricuspid repairs. Intensive and hospital stays were longer. In-hospital deaths (n = 3, all women) were comparable, with more atrial fibrillation in women. The median follow-up time was 3.44 (0.008-8.9) years. The ejection fraction, NYHA, and recurrent regurgitation were low and comparable and atrial fibrillation more frequent in women. The calculated 5-year survival and freedom from re-intervention were comparable (
CONCLUSIONS CONCLUSIONS
Despite women being older and sicker, with more complex valve pathology and subsequent replacement, early and mid-term mortality and the need for reoperation were low and comparable before and after propensity matching, which might be the result of the MIV setting combined with our patient-tailored decision-making. We believe that a multidisciplinary heart team approach is crucial to optimize patient outcomes in MIV, and it might also reduce the widely reported increased surgical risk in female patients. Further studies are needed to prove our findings.

Identifiants

pubmed: 37373938
pii: jpm13060949
doi: 10.3390/jpm13060949
pmc: PMC10305141
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

Eur J Cardiothorac Surg. 2012 Apr;41(4):734-44; discussion 744-5
pubmed: 22378855
Ann Cardiothorac Surg. 2013 Nov;2(6):744-50
pubmed: 24349976
Ann Thorac Surg. 2020 Mar;109(3):669-677
pubmed: 31830438
Interact Cardiovasc Thorac Surg. 2021 Aug 18;33(3):325-332
pubmed: 33893493
Circulation. 2002 Sep 10;106(11):1355-61
pubmed: 12221052
Ann Thorac Surg. 2008 Jun;85(6):2040-4; discussion 2045
pubmed: 18498816
J Thorac Cardiovasc Surg. 2006 Mar;131(3):547-57
pubmed: 16515904
Circ Cardiovasc Qual Outcomes. 2012 May;5(3):298-307
pubmed: 22576847
Ann Transl Med. 2021 Jan;9(1):60
pubmed: 33553353
Eur J Cardiothorac Surg. 2018 Jun 1;53(6):1112-1117
pubmed: 29684154
Eur J Cardiothorac Surg. 2022 Feb 18;61(3):695-702
pubmed: 34392335
Thorac Cardiovasc Surg. 2013 Jan;61(1):42-6
pubmed: 23258762
Interact Cardiovasc Thorac Surg. 2016 Nov;23(5):779-783
pubmed: 27365008
Innovations (Phila). 2011 Mar;6(2):84-103
pubmed: 22437892
Am J Cardiol. 2020 Apr 1;125(7):1083-1087
pubmed: 31982103
J Thorac Cardiovasc Surg. 2008 Nov;136(5):1205; discussion 1205-6
pubmed: 19026803
Ann Thorac Surg. 2013 Oct;96(4):1367-1373
pubmed: 23915585
J Am Heart Assoc. 2019 Sep 3;8(17):e013260
pubmed: 31438770
Lancet. 2006 Sep 16;368(9540):1005-11
pubmed: 16980116
Eur J Cardiothorac Surg. 2021 Jan 4;59(1):180-186
pubmed: 32776150
J Thorac Cardiovasc Surg. 2020 Aug;160(2):385-394.e1
pubmed: 31570218
J Thorac Cardiovasc Surg. 2018 Nov;156(5):1856-1866.e3
pubmed: 30343697
Circulation. 2003 Apr 1;107(12):1609-13
pubmed: 12668494
J Card Surg. 2014 Nov;29(6):766-71
pubmed: 25154766
Eur J Cardiothorac Surg. 2022 Oct 4;62(5):
pubmed: 35471499
Ann Thorac Surg. 2009 Jul;88(1 Suppl):S23-42
pubmed: 19559823
J Thorac Cardiovasc Surg. 2013 Mar;145(3):748-56
pubmed: 23414991
Eur Heart J. 2017 Sep 21;38(36):2739-2791
pubmed: 28886619
Ann Thorac Surg. 2011 Feb;91(2):401-5
pubmed: 21256279
J Thorac Cardiovasc Surg. 2019 Jul;158(1):86-94.e1
pubmed: 30797588
Ann Intern Med. 2008 Dec 2;149(11):787-95
pubmed: 19047025
Ann Thorac Cardiovasc Surg. 2007 Feb;13(1):21-6
pubmed: 17392666
Circulation. 2001 Sep 18;104(12 Suppl 1):I1-I7
pubmed: 11568020
Circulation. 2021 Oct 5;144(14):1172-1185
pubmed: 34606298
Scand J Surg. 2022 Dec;111(4):99-109
pubmed: 36112913
J Thorac Cardiovasc Surg. 2014 Nov;148(5):1989-1995.e4
pubmed: 24589199
Open Heart. 2020 Jul;7(2):
pubmed: 32690553

Auteurs

Laina Passos (L)

Heart Clinic Hirslanden, Witellikerstrasse 40, 8032 Zuerich, Switzerland.

Isabel Lavanchy (I)

Heart Clinic Hirslanden, Witellikerstrasse 40, 8032 Zuerich, Switzerland.

Thierry Aymard (T)

Heart Clinic Hirslanden, Witellikerstrasse 40, 8032 Zuerich, Switzerland.

Mohammed Morjan (M)

Department of Cardiac Surgery, Medical Faculty, University Hospital Duesseldorf, Heinrich-Heine-University Duesseldorf, Mooren Str. 5, 40225 Duesseldorf, Germany.

Ioannis Kapos (I)

Heart Clinic Hirslanden, Witellikerstrasse 40, 8032 Zuerich, Switzerland.

Roberto Corti (R)

Heart Clinic Hirslanden, Witellikerstrasse 40, 8032 Zuerich, Switzerland.

Juerg Gruenenfelder (J)

Heart Clinic Hirslanden, Witellikerstrasse 40, 8032 Zuerich, Switzerland.

Patric Biaggi (P)

Heart Clinic Hirslanden, Witellikerstrasse 40, 8032 Zuerich, Switzerland.

Diana Reser (D)

Heart Clinic Hirslanden, Witellikerstrasse 40, 8032 Zuerich, Switzerland.

Classifications MeSH